International Journal of Medicine and Data

Objective To explore the clinical effect of transcatheter arterial chemoembolization (TACE) combined with microwave ablation in the treatment of liver cancer. Methods 80 patients with liver cancer admitted to our hospital from April 2018 to April 2022 were selected as the subjects of this study. The patients were divided into two groups by double blind method: the reference group (n=40, transcatheter arterial chemoembolization) and the combined group (n=40, transcatheter arterial chemoembolization combined with microwave ablation); The therapeutic effects, AST, ALT and AFP were compared between the two groups. Results The effective rate of the combined group was higher than that of the reference group, with significant difference (P<0.05). There was no significant difference between the two groups in the levels of AST, ALT and AFP before treatment (P>0.05). After treatment, the levels of AST, ALT and AFP in the two groups were significantly lower than those before treatment, but the levels of AST, ALT and AFP in the combined group were significantly lower than those in the reference group, with significant difference between groups (P<0.05). Conclusion Transcatheter arterial chemoembolization combined with microwave ablation can improve the therapeutic effect and liver function of patients with liver cancer.

Transcatheter arterial chemoembolization; Microwave ablation; liver cancer